Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Charles River Laboratories International Inc Lowers High End Of Prior FY 2013 Revenue Guidance; Raises Low End Of Prior FY 2013 EPS Guidance To A Range Above Analysts' Estimates


Tuesday, 29 Oct 2013 04:30pm EDT 

Charles River Laboratories International Inc updated fiscal 2013 guidance and expects net sales growth in the range of 3.0%-3.5% (prior 3.0%-5.0%), net sales growth, constant currency in the range of 4.0%-4.5% (prior 4.0%-6.0%), GAAP EPS in the range of $2.23-$2.28 (prior $2.40-$2.50) and Non-GAAP EPS in the range of $2.85-$2.90 (prior $2.80-$2.90). The Company reported revenue of $1.130 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $1.169 billion and EPS of $2.83 for fiscal 2013. 

Company Quote